Oligonucleotides and methods for detecting hepatitis C viral nucleic acids
AssigneeQuest Diagnostics Investments Incorporated
InventorsRussell Baumann, Hasnah Hamdan, Michael Lewinski
Life of this patent
Estimating the term…
Abstract
The present invention provides methods and compositions for determining the presence and/or amount of HCV nucleic acids in a test sample. In particular, substantially purified oligonucleotide primers and probes are described that can be used for qualitatively and quantitatively detecting HCV nucleic acid in a test sample by amplification methods. The present invention also provides primers and probes for generating and detecting control nucleic acid sequences that provide a convenient method for assessing internal quality control of the HCV assay.
Claims7
A substantially purified oligonucleotide having a sequence selected from the group consisting of:
- (SEQ ID NO:3)
- 5′-CCG GGA GAG CCA TAG TGG TCT GCG-3′,
- (SEQ ID NO:4)
- 5′-TAA TAC GAC TCA CTA TAG GGG CAG AAA GCG TCT AGC
- CAT GGC GTA AAA TCC GGT AGT AAC TTG CTA ACC-3′,
- (SEQ ID NO:5)
- 5′-CTC GCA AGC ACC CTA TCA GGC AGT TAG TGC GGG TGT
- TGA ATG ATT TCC-3′,
- and
- (SEQ ID NO:6)
- 5′-TTG GCA ACA GTG GCA TGC ACC G-3′.
A method for producing an oligonucleotide that is a hybrid of lambda phage-HCV nucleic acid sequence, comprising:
- amplifying lambda phage DNA using a pair of oligonucleotide primers having the sequences set forth in SEQ ID NO:4 and SEQ ID NO:5 to provide a plurality of lambda phage-HCV hybrid amplicons;
- and
- reverse transcribing and purifying the resultant lambda phage-HCV hybrid RNA.
Dependencies are inferred from the claim text.